Teva gets FDA nod for breast cancer treatment

The pharmaceutical company reported the commercial launch of generic Arimidex.

Generic pharmaceuticals giant Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) said that the US Food and Drug Administration (FDA) has approved Teva's generic version of AstraZeneca's breast cancer drug Arimidex.

Based on IMS sales data, the branded drug has annual sales of about $916.8 million.

Teva said that it began its commercial launch of Anastrozole tablets 1 mg, the company’s generic version of AstraZeneca’s Arimidex. The product is used to treat certain forms of breast cancer in postmenopausal women.

Published by Globes [online], Israel business news - - on June 29, 2010

© Copyright of Globes Publisher Itonut (1983) Ltd. 2010

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018